Overview

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Status:
Completed

Trial end date:
2017-02-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.